Tech
OpenAI Acquires Orchestra Bio to Bring AI Into Drug Development
OpenAI is acquiring Orchestra Bio to add AI-powered operations to life sciences research and development.
What happened
OpenAI is acquiring Orchestra Bio, a move focused on bringing AI-powered operations to life sciences research and development. The stated aim is to help biopharmaceutical teams accelerate drug development and advance new treatments. The source provides no transaction value, closing date, or further details about Orchestra Bio’s operations.
Why it matters
The acquisition is intended to speed biopharmaceutical drug development by applying AI to research and development operations, potentially advancing new treatments faster.
Source: OpenAI News